Skip to main content

Stem-Cell Investments on the Rise

HENDERSON, NV / ACCESSWIRE / July 20, 2018 / The global stem cell market is expected to reach US 270.5 Billion by 2025, while increasing at a compound annual growth rate of 13.8% during the period from 2017 to 2025. All this comes from a report published by Transparency Market Research. From a global perspective, North America accounts for a leading share in the market due to rising instances of chronic diseases, increasing research investment and technological progress. The stem cells market in North America is projected to be worth USD 167.33 Billion by 2025.

The lead analyst of the report explains, "The growing prevalence of chronic diseases and increasing investments of pharmaceutical and biopharmaceutical companies in stem cell research are the key driving factors for the stem cells therapeutics market. The growing number of stem cell donors, improved stem cell banking facilities, and increasing research and development are other crucial factors serving to propel the market.

Here are a few stem cell companies that can help make you money in this growing market:

BioRestorative Therapies, Inc. (BRTX)

Market cap: $11.3 million; current share price: $1.70

BioRestorative Therapies, Inc., a life sciences company focused on stem cell-based therapies, recently reported the findings from Defined Health, which was engaged by the Company to conduct an independent review of BRTX-100, the Company's lead cell therapy candidate designed to treat chronic Lumbar Disc Disease (cLDD). Defined Health is a well-recognized business development and strategy consulting firm that has worked with many of the leading companies in the pharmaceutical, biotech and healthcare industries for over 25 years.

The Company plans to include the results of the review as it further refines its BRTX-100 program (that has been approved by the FDA to commence a Phase 2 clinical trial) by actively engaging in discussions with potential licensing partners, co-development and commercialization activities.

Since announcing this news, the Company has seen increased interest from investors this summer that could potentially lead to a major move in the near future.

Vericel (VCEL)

Market cap: $424 million; current share price: $10.00

Vericel bases its treatment in tissue collection from the patient. Its two lead products, Carticel and Epicel, are seeking to treat cartilage defects in the knee and patients with burns greater than or equal to 30 percent of total body surface area respectively.

The company initiated a collaboration with the private company Innovative Cellular Therapeutics. Vericel has the intention to use the collaboration to bring its cell therapy products to patients in Asia.

In March, the company announced positive 2017 financial results with an 18 percent increase to $63.9 million from $54.4 million year over year.

''We successfully executed the launch of MACI and expanded Epicel utilization in 2017,'' Nick Colangelo, Vericel president and CEO said. ''These successes, combined with a strong balance sheet and an expanded sales force in 2018, have positioned the company for continued strong revenue growth in the years ahead.''

Sangamo Therapeutics (SGMO)

Market cap: $1.5 billion; current share price: $15.10

First founded as Sangamo BioSciences - and changed to therapeutics in early 2017 - this company seeks to develop new medicines to treat genetic diseases. The company has 12 drug candidates in its pipeline, all involved in different stages of trials and research. In February, Sangamo announced the regulatory agency in the UK granted the company permission to begin a new phase ½ clinical trial for SB-FIX. Also in February, the company announced a new collaboration to develop a next-generation cell therapy for cancer with Kite Pharma, a subsidiary of Gilead (GILD).

''We are excited by Kite's commitment to driving innovation in this field and look forward to working together to realize the full promise of cell therapy in treating cancer, ''Sandy Macrae, president and CEO of Sangamo said in the press release.

Cellular Biomedicine Group (NASDAQ: CBMG)

Market cap: $339.27 million; current share price: $19.95

This company has its eyes set on China as it hopes to become a leader in the specialty pharmaceutical market for cell therapeutics. Late 2017, Cellular Biomedicine opened a new Shanghai-based joint laboratory and manufacturing facility.

Earlier this year, the company additionally announced a new cell therapy manufacturing agreement with GE Healthcare.

''This is a productivity revolution in the CAR-T space,'' Tony Liu, CEO of the company said in the release. ''This new generation of semi-automated and standardized CAR-T manufacturing capabilities created by GE Healthcare and CBMG may allow cell therapy to provide an optimal platform and opportunity for general oncology patients.''

Caladrius Biosciences (CLBS)

Market cap: $52 million; current share price: $5.52

Caladrius is investigating its lead product candidate CLBS03 to treat recent-onset type 1 diabetes, currently in a phase 2 clinical trial. The company plans for this treatment to be autologous.

In March, Caladrius had two big announcements: the first one being that it had acquired the rights to Shire's data set and regulatory filings for the CD43+ cell therapy program to treat refractory angina. Following that, the company released phase 2 CLBS03 interim analysis which show the trial has been successful thus far.

''The results of this interim analysis show that CLBS03 remains well-tolerated and that a positive outcome for therapeutic effect at the end of the trial remains a statistical possibility,'' David Mazzo, Caladrius CEO, said.

VistaGen Therapeutics (VTGN)

Market cap: $31 million; current share price: $1.35

This biopharmaceutical company is seeking to develop and commercialize new chemical entities with regenerative potential and cellular therapies involving stem cell-derived blood, cartilage, heart and liver cells. It also owns the subsidiary VistaStem, focused on using human stem cell technology to make human health predictions.

In early 2018 VistaGen received FDA fast track designation for AV-101 to treat major depressive disorder. It's meant to act as a ketamine-like antidepressant without its negative central nervous system side-effects.

Conclusion

If you are looking to get involved in the booming stem cell market, these stocks aren't a bad start.

Legal Disclaimer

Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. ACR Communication, LLC, which owns Microcapspeculators.com, is not registered with Finra or any other financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. ACR Communication, LLC [and/or] Microcapspeculators.com does not have a position in the securities mentioned herein and may increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice. ACR Communication LLC, which owns Microcapspeculators.com, is compensated for its services in the form of cash-based compensation or in equity in the companies it writes about, or a combination of the two. ACR Communication, LLC has been compensated one thousand dollars cash for this article and three thousand dollars total by Regal Consulting. LLC, for news commentary articles for BRTX. BRTX and Regal Consulting, LLC were given an opportunity to edit information included in this article. This article is based solely on public information and the opinions of ACR Communication, LLC, which believes the news commentary to include accurate and complete information. ACR Communication, LLC, will not buy or sell any shares in stocks contained within this article for forty eight hours after this article's distribution.

For Full Legal Disclaimer Click Here.

Contact Information:

Company Name: Microcap Speculators

Contact Person: Media Manager

Email: info@microcapspecualtors.com

Phone: 1-702-720-6310

Country: United States

Website: http://microcapspeculators.com/

SOURCE: ACR Communications LLC

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.